Nordic Capital to invest €450m in LEO Pharma.

Nordic Capital, a global healthcare private equity investor, agreed to invest €450m ($536m) in LEO Pharma, a multinational Danish pharmaceutical company, from LEO Foundation, a commercial foundations. The transaction is subject to customary regulatory approvals and completion is expected to take place in the first half of 2021. “I am very enthusiastic about the opportunity to welcome Nordic Capital onboard. With Nordic Capital we have secured a supportive and seasoned partner going forward with deep medical expertise and a strong track record supporting value creation in innovative healthcare businesses globally. Further, their strong Scandinavian heritage lends itself to a common cultural understanding and approach. I am confident that the partnership will further enhance the considerable growth potential of LEO Pharma, and it is a natural next step on LEO Pharma’s journey,” Jesper Mailind, LEO Foundation CEO.